Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21940521 | 0.98 | — | — | |
| SCHEMBL15841353 | 0.86 | POLB (0.44) | POLBHTTNPSR1KDM4EMAPT | |
| SCHEMBL8221437 | 0.84 | POLB (0.46) | POLBHTTNPSR1KDM4EMAPT | |
| SCHEMBL18360210 | 0.76 | — | — | |
| SCHEMBL21761728 | 0.72 | POLB (0.39) | POLBHTTNPSR1KDM4EMAPT | |
| SCHEMBL11408346 | 0.72 | — | — | |
| SCHEMBL11408342 | 0.72 | — | — | |
| SCHEMBL8209943 | 0.71 | ALDH1A1 (0.46) | POLBHTTNPSR1KDM4EMAPT | |
| SCHEMBL21940347 | 0.71 | KMT2A (0.46) | POLBHTTNPSR1KDM4EMAPT | |
| SCHEMBL28224064 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025226286-A1 | SYSTEMS AND METHODS FOR SIMULTANEOUS IMAGING OF MULTIPLE POSITRON EMISSION TOMOGRAPHY (PET) TRACERS | MULTIF UNCTIONAL IMAGING LLC (US) | 2025-10-30 | — | — | WO | claimed |
| US-20250329024-A1 | SYSTEMS AND METHODS FOR SIMULTANEOUS IMAGING OF MULTIPLE POSITRON EMISSION TOMOGRAPHY (PET) TRACERS | MultiFunctional Imaging LLC (US) | 2025-10-23 | — | — | US | claimed |
| US-20220378913-A1 | METHODS FOR DIAGNOSIS AND TREATMENT | GMDX CO PTY LTD (AU) | 2022-12-01 | — | — | US | claimed |
| CN-115040667-A | Nuclide-iodized oil homogeneous preparation and preparation method and application thereof | 厦门大学 | 2022-09-13 | — | — | CN | claimed |
| EP-4048814-A1 | METHODS FOR DIAGNOSIS AND TREATMENT | GMDx Co Pty Ltd (AU) | 2022-08-31 | — | — | EP | claimed |
| US-20260144846-A1 | Modulation Of Tumor Immunity By Protein-Mediated O2 Delivery | OMNIOX, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12533427-B2 | Radioactive antitumor agent | NATIONAL INSTITUTES FOR QUANTUM SCIENCE & TECHNOLOGY (JP) | 2026-01-27 | — | — | US | disclosed |
| US-12522618-B2 | Copper complexes for treatment of neurodegenerative disorders | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2026-01-13 | — | — | US | disclosed |
| US-12473522-B2 | Methods and systems for cell labeling and imaging | CELLFE, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| WO-2025226286-A1 | SYSTEMS AND METHODS FOR SIMULTANEOUS IMAGING OF MULTIPLE POSITRON EMISSION TOMOGRAPHY (PET) TRACERS | MULTIF UNCTIONAL IMAGING LLC (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250329024-A1 | SYSTEMS AND METHODS FOR SIMULTANEOUS IMAGING OF MULTIPLE POSITRON EMISSION TOMOGRAPHY (PET) TRACERS | MultiFunctional Imaging LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250295869-A1 | ADMINISTRATION OF HYPOXIA ACTIVATED PRODRUGS AND ANTIANGIOGENIC AGENTS FOR THE TREATMENT OF CANCER | THRESHOLD PHARMACEUTICALS, INC. | 2025-09-25 | — | — | US | disclosed |
| CN-110585607-B | System and method for use in emission guided radiation therapy | 反射医疗公司 | 2022-07-19 | — | — | CN | disclosed |
| EP-4021454-A1 | COPPER-ATSM FOR TREATING NEURODEGENERATIVE DISORDERS ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION | Research Institute at Nationwide Children's Hospital (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20220175973-A1 | METHOD FOR PRODUCING RADIOPHARMACEUTICAL AND RADIOPHARMACEUTICAL | National Institutes for Quantum Science and Technology (JP) | 2022-06-09 | — | — | US | disclosed |
| US-20220160823-A1 | MODULATION OF TUMOR IMMUNITY BY PROTEIN-MEDIATED O2 DELIVERY | OMNIOX, INC. | 2022-05-26 | — | — | US | disclosed |
| CN-112962125-B | Method for preparing 64Ni target and 64Cu nuclide and application thereof | 原子高科股份有限公司 | 2022-05-17 | — | — | CN | disclosed |
| US-20220096867-A1 | SYSTEMS AND METHODS FOR USE IN EMISSION GUIDED RADIATION THERAPY | OXFORD FINANCE LLC | 2022-03-31 | — | — | US | disclosed |
| WO-2022064812-A1 | METHOD FOR PRODUCING RADIOACTIVE LABELED SUBSTANCE, DEVICE FOR PRODUCING RADIOACTIVE LABELED SUBSTANCE, AND METHOD FOR EVAPORATING AND CONCENTRATING RADIOACTIVE METAL NUCLIDE | 国立研究開発法人量子科学技術研究開発機構 | 2022-03-31 | — | — | WO | disclosed |
| US-11266686-B2 | Metal complexes and methods of treatment | PROCYPRA THERAPEUTICS LLC (US) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533427-B2 | Radioactive antitumor agent | IDH2, MT-CO1, ALDH2 | POLB 1496/4885HTT 2193/4885NPSR1 2587/4885 |
| US-11266686-B2 | Metal complexes and methods of treatment | NLN, PNMT, BDNF | POLB 3985/4885HTT 230/4885NPSR1 34/4885 |
| US-20260144846-A1 | Modulation Of Tumor Immunity By Protein-Mediated O2 Delivery | CD4, HIF1A, HIF1AN | POLB 1059/4885HTT 2657/4885NPSR1 3868/4885 |
| US-20220175973-A1 | METHOD FOR PRODUCING RADIOPHARMACEUTICAL AND RADIOPHARMACEUTICAL | CTH, MGMT, TST | POLB 3451/4885HTT 1216/4885NPSR1 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.